A systematic review of the effectiveness of adalimumab

130
References
70. Watson K, Hyrich KL, Lunt M, Silman A,
Symmons D, BSR Biologics Register. Infliximab
and non-methotrexate DMARDs for rheumatoid
arthritis: efficacy in clinical practice. Arthritis
Rheum 2004;50(Suppl):S190.
71. Electronic Medicines Compendium. Schering-
Plough. Remicade 100 mg powder for concentrate
for solution for infusion. Summary of product
characteristics. URL: http://emc.medicines.org.uk/
emc/industry/default.asp?page=displaydoc.asp&
documentid=3236. Accessed 14 June 2005.
72. Buch MH, Marzo-Ortega H, Bingham SJ, Emery
P. Long-term treatment of rheumatoid arthritis
with tumour necrosis factor a blockade: outcome
of ceasing and restarting biologicals [1].
Rheumatology 2004;43:243–4.
73. Buch MH, Linsay S, Bryer D, Fairclough A,
Rees-Evans B, Emery P. Incidence of influsionrelated
reactions in patients receiving infliximab:
recommendations for administration guidelines.
Ann Rheum Dis 2004;63(Suppl):285.
74. Durez P, Van den Bosch F, Corluy L, Veys EM,
De Clerck L, Peretz A, et al. A dose adjustment in
patients with rheumatoid arthritis not optimally
responding to a standard dose of infliximab of
3 mg/kg every 8 weeks can be effective: a Belgian
prospective study. Rheumatology 2005;44:465–8.
75. Ehlers S. Why does tumour necrosis factor
targeted therapy reactivate tuberculosis?
J Rheumatol 2005;32(Suppl 74):35–9.
76. Wallis RS, Broder M, Wong J, Beenhouwer D.
Granulomatous infections due to tumour necrosis
factor blockade: correction. Clin Infect Dis 2004;
39:1254–5.
77. Ormerod LP. Tuberculosis and anti-TNF-
treatment. Thorax 2004;59:921.
78. Gardam MA, Keystone EC, Menzies R, Manners S,
Skamene E, Long R, et al. Anti-tumour necrosis
factor agents and tuberculosis risk: mechanisms of
action and clinical management. Lancet Infect Dis
2003;3:148–55.
79. Charles PJ, Smeenk RJT, De Jong J, Feldmann M,
Maini R. Assessment of antibodies to doublestranded
DNA induced in rheumatoid arthritis
patients following treatment with infliximab, a
monoclonal antibody to tumour necrosis factor :
findings in open-label and randomised placebo
controlled trials. Arthritis Rheum 2000;43:2383–90.
80. Bennett SP, Sawyer S, Baker A, Arden NK,
Edwards CJ. Patient preferences in choosing anti-
TNF therapies. Rheumatology 2005;44(Suppl 1):
i151.
81. Westhovens R, Houssiau F, Joly J, Everitt DE,
Bouman-Thio E, Zhu Y, et al. A phase I study
assessing the safety, clinical response, and
pharmacokinetics of an experimental infliximab
formulation for subcutaneous or intramuscular
administration in patients with rheumatoid
arthritis. J Rheumatol 2006;33:847–53.
82. Fraenkel L, Bogardus ST, Concato J, Felson DT,
Wittink DR. Patient preferences for treatment of
rheumatoid arthritis. Ann Rheum Dis 2004;
63:1372–8.
83. National Institute for Health and Clinical
Excellence. Guidance on the use of etanercept and
infliximab for the treatment of rheumatoid
arthritis. URL: http://www.nice.org.uk/pdf/
RA_A4_summary.pdf. Accessed 23 May 2005.
84. British Society for Rheumatology. Guidelines for
prescribing TNF blockers in adults with
rheumatoid arthritis. URL: www.rheumatology.
org.uk. Accessed 14 June 2001.
85. British Society for Rheumatology. Anti-TNFa
agents in rheumatoid arthritis. Evidence for the
5-year review of anti-TNF. Submission to the
National Institute for Health and Clinical
Evidence; 2005.
86. Ledingham J, Deighton C. Update on the British
Society for Rheumatology guidelines for
prescribing TNF blockers in adults with
rheumatoid arthritis (update of previous
guidelines of April 2001). Rheumatology 2005;
44:157–63.
87. Watson K, Hyrich K, Symmons D, Silman A, BSR
Biologics Register. British Society for
Rheumatology Biologics Register (BSRBR): the
experience of rheumatoid arthritis patients
receiving infliximab or etanercept to December
2003 [abstract LB1]. Rheumatology 2004;
43(Suppl 2):ii1.
88. Arnett F, Edworthy S, Bloch D. The American
Rheumatism Association 1987 revised criteria for
the classification of rheumatoid arthritis. Arthritis
and Rheum 1988;31:315–24.
89. Harrison B, Symmons D, Barrett E, Silman A.
The performance of the 1987 ARA classification
criteria for rheumatoid arthritis in a population
based cohort of patients with early inflammatory
polyarthritis. J Rheumatol 1998;25:2324–30.
90. Gardiner PV, Bell AL, Taggart AJ, Wright G,
Kee F, Smyth A, et al. A potential pitfall in the use
of the Disease Activity Score (DAS28) as the main
response criterion in treatment guidelines for
patients with rheumatoid arthritis. Ann Rheum Dis
2005;64:506–7.
91. Cohen M. Accentuate the positive: we are better
than guidelines. Arthritis Rheum 1997;40:2–4.
92. Tannenbaum S. What physicians know. N Engl J
Med 1993;329:1268–71.
93. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E.
The Disease Activity Score is not suitable as the
sole criterion for initiation and evaluation of anti-